| Name | Title | Contact Details |
|---|
Navicent Health was incorporated on November 17, 1994, as a nonprofit corporation whose primary purpose is to coordinate the Medical Center, Navicent Health and other affiliated entities in their mission of providing a comprehensive continuum of high quality, reasonably priced healthcare services to the region. Navicent Health has 830 beds for medical, surgical, rehabilitation and hospice purposes. The Medical Center, Navicent Health – a nationally recognized tertiary teaching hospital and the primary teaching hospital for Mercer University School of Medicine - includes but is not limited to: •Peyton Anderson Cancer Center, Navicent Health, a provider of comprehensive cancer care. Our services cover the continuum of cancer care, from screening and diagnosis through treatment and into survivorship. •Emergency Center, Navicent Health provides access to our Level 1 Trauma Center and includes helipad capability. The Emergency Center, along with our three urgent care locations, treat over 120,000 visitors per year. •Family Birth Center, Navicent Health has spacious labor and delivery suites, focuses on providing a family-friendly and family-centered environment for expectant mothers and their babies, and specializes in care for difficult pregnancies. •Heart Center, Navicent Health provides a full range of services for the prevention, diagnosis and treatment of cardiovascular disease, including congestive heart failure. •Rehabilitation Hospital, Navicent Health is the oldest and most experienced medical rehabilitation provider in central Georgia providing comprehensive services to help patients achieve their highest level of mobility and independence. •Beverly Knight Olson Children`s Hospital, Navicent Health, the region`s only dedicated pediatric hospital Navicent Health is the region`s leading provider of a comprehensive continuum of services. Whatever your healthcare needs, Navicent Health is here to assist you and your loved ones.
Dsr Pharmaceuticals is a Playa Del Rey, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Harrow Health, Inc. (NASDAQ: HROW) owns a portfolio of healthcare businesses, including ImprimisRx, the nation`s leading ophthalmology outsourcing facility and pharmaceutical compounding business.
Syner-G BioPharma Group is the premier solution provider of Chemistry, Manufacturing, and Controls (CMC) services for the life sciences industry. The company`s approach is based on CMC 360™, a fully integrated suite of CMC solutions that encompasses pharmaceutical development, regulatory affairs, and quality/cGxP compliance. The entire Syner-G organization is built around the premise of guiding small molecule, biologics, cell and gene therapy, and medical device innovators through the CMC process.
Vitality has developed a new class of cannabinoid prodrugs (cannabosides), which enable selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Site-specific delivery could enable potent local therapeutic effects while reducing or avoiding the systemic delivery of THC to the brain. Currently, the psychoactivity of THC limits the dose of cannabinoids that can be used for treatment of pain and inflammation. Studies have shown that the cannabinoid system is a potent mediator of pain relief and inflammation, as studies have shown that cannabinoid drugs can in some cases be far more potent than opiates for pain relief, and far more potent than aspirin or corticosteroids for providing anti-inflammatory effects. For example, cannabinoid drugs have been shown to be nearly 10 times as potent as morphine for neuropathic pain relief. Studies have also shown they can be 20 times as potent as aspirin, and twice as potent as corticosteroids for treating inflammation. But currently, the “elephant in the room” remains, which is that the desired potent effects cannot be achieved when high doses of THC enter the bloodstream and brain. Patients are forced to limit their doses, so targeted administration is critical. Our solution goes to the heart of this issue and offers an alternative means to increase the beneficial dosage, right at the site of disease – where it matters most, and relegates the psychoactive nature of the drug to a manageable side effect.